

Serial No.: 10/019633
Docket No.: BB1386 US NA

Page 5

REMARKS

The specification has been amended in two places on pages 8-9 and page 21, to remove reference to the following URL: www.ncbi.nlm.nih.gov/BLAST/.

Claims 25-37 are pending. Claims 1-24 have been canceled. New Claims 25-37 are meant to replace original Claims 1-9, 11-13, 16, and 18-22, drawn to a polynucleotide and first method of using. The term "recombinant DNA" is used to replace "chimeric gene" from the original claims, support for which can be found on page 12, lines 28-31. Support for the percent identities cited in claims 25-27 can be found on page 7, lines 18-24. Thus, no new matter has been added.

RESPONSE TO RESTRICTION REQUIREMENT


Applicants hereby provisionally elect the subject matter of Group I, claims 1-9, 11-13, 16, and 18-22, and as required under 37 CFR 1.499, a further election of invention (A) is made to a polynucleotide of SEQ ID NO:1 or a corresponding polypeptide of SEQ ID NO:2, without traverse, for further prosecution in the instant application subject to Applicants' right to pursue the non-elected subject matter in a divisional application or applications pursuant to 35 USC §121.

It is believed that new claims 25-37 correspond to claims 1-9, 11-13, 16, and 18-22 which constituted the subject matter of Group I.

In view of the foregoing amendments and remarks, it is respectfully submitted that this case is in form for allowance which allowance is respectfully requested.

Please credit any overpayment or charge any fees associated with the filing of this response or credit any overpayment to Deposit Account 04-1928 (E. I. du Pont de Nemours and Company).

Respectfully submitted,



Lynne M. Christenbury

Attorney For Applicants

Registration No. 30,971

Telephone: 302-992-5481

Facsimile: 302-892-1026

Dated: January 5, 2004